TGTX TG Therapeutics
- 21.000
- -0.230-1.08%
TG Therapeutics News
$1000 Invested In TG Therapeutics 5 Years Ago Would Be Worth This Much Today
TG Therapeutics (NASDAQ:TGTX) has outperformed the market over the past 5 years by 9.05% on an annualized basis producing an average annual return of 22.44%. Currently, TG Therapeutics has a market
Subdued Growth No Barrier To TG Therapeutics, Inc. (NASDAQ:TGTX) With Shares Advancing 29%
TG Therapeutics, Inc. (NASDAQ:TGTX) shares have continued their recent momentum with a 29% gain in the last month alone. Unfortunately, the gains of the last month did little to right the losses
TG Therapeutics Currently Up Seven Consecutive Days, On Track for Longest Winning Streak Since September 2020 -- Data Talk
TG Therapeutics, Inc. ( TGTX ) is currently at $20.45, up $0.54 or 2.71% --Would be highest close since Jan. 9, 2024, when it closed at $21.01 --Currently up eight of the past nine days --Currently
TG Therapeutics (NASDAQ:TGTX) Delivers Shareholders Solid 15% CAGR Over 5 Years, Surging 6.6% in the Last Week Alone
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on a lighter note, a good company can see its share price rise well
Insider Sale: Director Sagar Lonial Sells 25,933 Shares of TG Therapeutics Inc (TGTX)
TG Therapeutics(TGTX.US) Director Sells US$432.89K in Common Stock
$TG Therapeutics(TGTX.US)$ Director Lonial Sagar sold 25,933 shares of common stock on Jun 17, 20, 2024 at an average price of $16.69 for a total value of $432.89K.Source: Announcement What is stateme
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
PALM BEACH, Fla., June 11, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than doubled. In 2000, it
Express News | Calstrs: Decided to Vote Against Laurence Charney, Yann Echelard, Kenneth Hoberman, Daniel Hume, Sagar Loniel, Michael Weiss at TG Therapeutics' AGM
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PDF Version Fireside chat scheduled for Tuesday, June 11, 2024, at 1:20 PM ETNEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Wei
(TGTX) - Analyzing TG Therapeutics's Short Interest
TG Therapeutics's (NYSE:TGTX) short percent of float has fallen 9.38% since its last report. The company recently reported that it has 34.30 million shares sold short, which is 24.54% of all regular s
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
PDF Version Fireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ETNEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. We
Express News | TG Therapeutics Discloses Presentations For Post-marketing Studies Being Undertaken For BRIUMVI (Ublituximab-xiiy) In Patients With Relapsing Forms Of Multiple Sclerosis At 2024 Consortium Of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics Announces Presentations for BRIUMVI (Ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
PDF Version NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken
TG Therapeutics (NASDAQ:TGTX) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI (Ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
PDF Version NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Peering Into TG Therapeutics's Recent Short Interest
TG Therapeutics's (NYSE:TGTX) short percent of float has fallen 6.31% since its last report. The company recently reported that it has 35.71 million shares sold short, which is 25.55% of all regular s
TG Therapeutics Under Pressure: Navigating the Perils of Government Contracts and Compliance Hurdles
TG Therapeutics | 10-Q: Quarterly report
New Forecasts: Here's What Analysts Think The Future Holds For TG Therapeutics, Inc. (NASDAQ:TGTX)
Shareholders in TG Therapeutics, Inc. (NASDAQ:TGTX) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts greatly increased their
Analysis
Price Target
No Data
